Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Stocks in this Quantisnow insightHealth Care
Historical context for ADIL
Across the 10 sessions after earlier ADIL headlines, the stock closed higher 3 times and lower 7 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ADIL | SPY |
|---|---|---|---|
| Mar 24, 2026 | Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans | -8.2% | -0.3% |
| Mar 6, 2026 | Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update | -7.1% | -1.3% |
| Mar 3, 2026 | Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement | -7.3% | -0.9% |
| Feb 24, 2026 | Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement | +4.7% | +0.7% |
| Feb 23, 2026 | Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One | -4.9% | -1.0% |
| Feb 17, 2026 | Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | -5.3% | +0.2% |
Quantisnow market dataNASDAQ
ADIL
Adial Pharmaceuticals Inc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Get push alerts for ADIL
Full ADIL profile on Quantisnow Follow ADIL and get a push notification the moment its next story breaks.